1007-42-7

Basic information

• Product Name: L-Histidine hydrochloride
• Synonyms: H-His-OH.xHCl;L-HISTIDINE DIHYDROCHLORIDE;L-Histidine hydrochloride solution;histidine hydrochloride;Crystalline2HCl;L-Histidine hydrochloride;L-Histdine Dihydrochloride;(2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid hydrochloride
• CAS NO: 1007-42-7
• Molecular Formula: C₆H₉N₃O₂*2ClH
• Molecular Weight: 191.62
• EINECS: 227-890-5
• Mol File: 1007-42-7.mol
• Article Data: 2

Chemical Properties

• Melting Point: 240-245 °C (dec.)
• Boiling Point: 458.9oC/ at 760 mmHg
• Flash Point: 231.3oC
• Appearance: /
• Vapor Pressure: 3.25E-09mmHg at 25°C
• Storage Temp.: 2-8°C
• CAS DataBase Reference: L-Histidine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: L-Histidine hydrochloride(1007-42-7)
• EPA Substance Registry System: L-Histidine hydrochloride(1007-42-7)

Safety Data

• Safety Statements: 22-24/25
• RIDADR: UN 1789 8/PG 3
• WGK Germany: 3
• F: 3-10
• Hazardous Substances Data: 1007-42-7(Hazardous Substances Data)

Usage

Purification Methods

The dihydrochloride crystallises from water or aqueous EtOH and is washed with acetone, then diethyl ether. Alternatively convert it to the histidine di-(3,4-dichlorobenzenesulfonate) salt by dissolving 3,4-dichlorobenzenesulfonic acid (1.5g/10mL) in the aqueous histidine solution with warming, and then the solution is cooled in ice. The resulting crystals (m 280o dec) can be recrystallised from 5% aqueous 3,4-dichlorobenzenesulfonic acid, then dried over CaCl2 under vacuum, and washed with diethyl ether to remove Purification of Biochemicals — Amino Acids and Peptides excess reagent. The dihydrochloride can be regenerated by passing the solution through a Dowex-1 (Cl-form) ion-exchange column. The solid is obtained by evaporation of the solution on a steam bath or better in a vacuum. [Greenstein & Winitz, The Amino Acids Vol 3 p 1976 1961, Beilstein 25/16 V 366.]

InChI:InChI=1/C6H9N3O2.ClH/c7-5(6(10)11)1-4-2-8-3-9-4;/h2-3,5H,1,7H2,(H,8,9)(H,10,11);1H

Upstream product

• 1604-44-0 N-α-trifluoroacetyl-L-histidine methyl ester 
• 4467-54-3 l-histidine methyl ester dihydrochloride 
• 160999-36-0 (2S,5R)-2-<(1-Benzylimidazol-5-yl)methyl>-2,5-dihydro-3,6-dimethoxy-5-isopropylpyrazine 

Downstream Products

• 17791-52-5 N-(tert-butoxycarbonyl)-L-histidine 
• 4467-54-3 l-histidine methyl ester dihydrochloride 

Relevant articles and documents

Alkylated histidine based short cationic antifungal peptides: Synthesis, biological evaluation and mechanistic investigations

Current clinically used antifungal agents suffer from several drawbacks that have urgently necessitated the development of new antifungal agents with unusual mechanisms of action. In this context, antifungal peptides (AFPs) open up new perspectives in drug design by providing an entire range of highly selective and nontoxic pharmaceuticals. Here, we report the development of novel short AFPs with the synthesis of two series of tripeptide based compounds named as His(2-alkyl)-Arg-Lys (series I) and His(2-alkyl)-Arg-Arg (series II). The series II peptides were found to be selectively active against Cryptococcus neoformans whereas some peptides displayed encouraging activities against other fungal strains such as Candida albicans, Candida kyfer, Aspergillus Niger and Neurospora crassa. The cytotoxic experiments were performed on active compounds using Hek-293 and HeLa cells which exhibited negligible cytotoxic effect up to the highest test concentration. Further, the most potent peptide was subjected to mechanistic studies using TEM analysis. Two sets of SUVs mimicking microbial membrane and mammalian membrane were treated with the most potent peptide. The results of this study were found to be perfectly in corroboration with the antifungal activity in relation to the differences between microbial and mammalian cell membrane composition, thereby, indicating that the reported peptides may also be less susceptible to the common mechanisms of drug resistance.